» Articles » PMID: 33426229

Urinary Bladder Reconstruction Using Autologous Collagenous Connective Tissue Membrane "Biosheet®" Induced by In-body Tissue Architecture: A Pilot Study

Overview
Journal Regen Ther
Date 2021 Jan 11
PMID 33426229
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: In-body tissue architecture (iBTA) technology, based on cell-free tissue engineering, can produces collagenous tissues for implantation by subcutaneous embedding a designed mold. The aim of this study was to evaluate the biocompatibility of iBTA-induced "Biosheet®" collagenous sheets, as scaffold materials for bladder reconstruction.

Methods: Canine Biosheet® implants were prepared by embedding molds into subcutaneous pouches in beagles for 8 weeks. A part of canine bladder wall was excised (2 × 2 cm) and repaired by patching the same sized autologous Biosheet®. The Biosheet® implants were harvested 4 weeks (n = 1) and 12 weeks (n = 3) after the implantation and evaluated histologically.

Results: No disruption of the patched Biosheet® implants or urinary leakage into the peritoneal cavity was observed during the entire observation periods. There were no signs of chronic inflammation or Biosheet® rejection. The urine-contacting surface of luminal surface of the Biosheet® was covered with a multicellular layer of urothelium cells 4 weeks after implantation. α-SMA-positive muscle cells were observed at the margin of the Biosheet® implants at 12 weeks after the implantation. In addition, in the center of the Biosheet® implants, the formation of microvessels stained as α-SMA-positive was observed.

Conclusion: Biosheet® implants have biocompatibility as a scaffold for bladder reconstruction, indicating that they may be applicable for full-thickness bladder wall substitution. Further studies are required for definitive evaluation as a scaffold for bladder reconstruction.

Citing Articles

Recent advances in innovative biomaterials for promoting bladder regeneration: processing and functionalization.

Zhang Y, Ding F, Han J, Wang Z, Tian W Front Bioeng Biotechnol. 2025; 12():1528658.

PMID: 39834643 PMC: 11743525. DOI: 10.3389/fbioe.2024.1528658.


Bladder Reconstruction in Cats Using In-Body Tissue Architecture (iBTA)-Induced Biosheet.

Fujita N, Sugiyama F, Tsuboi M, Nakamura H, Nishimura R, Nakayama Y Bioengineering (Basel). 2024; 11(6).

PMID: 38927851 PMC: 11200650. DOI: 10.3390/bioengineering11060615.


Evaluation of Skin Wound Healing with Biosheets Containing Somatic Stem Cells in a Dog Model: A Pilot Study.

Maeta N, Iwai R, Takemitsu H, Akashi N, Miyabe M, Funayama-Iwai M Bioengineering (Basel). 2024; 11(5).

PMID: 38790301 PMC: 11118178. DOI: 10.3390/bioengineering11050435.


Strategies of Bladder Reconstruction after Partial or Radical Cystectomy for Bladder Cancer.

Zeng X, Wu Y Mol Biotechnol. 2024; .

PMID: 38761327 DOI: 10.1007/s12033-024-01163-0.


Successful reconstruction of the rat ureter by a syngeneic collagen tube with a cardiomyocyte sheet.

Yamamoto S, Matsui K, Kinoshita Y, Sasaki H, Sekine H, Saito Y Regen Ther. 2023; 24:561-567.

PMID: 37868722 PMC: 10584669. DOI: 10.1016/j.reth.2023.10.001.


References
1.
Badylak S . Xenogeneic extracellular matrix as a scaffold for tissue reconstruction. Transpl Immunol. 2004; 12(3-4):367-77. DOI: 10.1016/j.trim.2003.12.016. View

2.
Brown A, Farhat W, Merguerian P, Wilson G, Khoury A, Woodhouse K . 22 week assessment of bladder acellular matrix as a bladder augmentation material in a porcine model. Biomaterials. 2002; 23(10):2179-90. DOI: 10.1016/s0142-9612(01)00350-7. View

3.
Kurzrock E . Pediatric enterocystoplasty: long-term complications and controversies. World J Urol. 2008; 27(1):69-73. DOI: 10.1007/s00345-008-0335-3. View

4.
Komura M, Komura H, Satake R, Suzuki K, Yonekawa H, Ikebukuro K . Fabrication of an anatomy-mimicking BIO-AIR-TUBE with engineered cartilage. Regen Ther. 2019; 11:176-181. PMC: 6700413. DOI: 10.1016/j.reth.2019.07.004. View

5.
Veiseh O, Vegas A . Domesticating the foreign body response: Recent advances and applications. Adv Drug Deliv Rev. 2019; 144:148-161. PMC: 6774350. DOI: 10.1016/j.addr.2019.08.010. View